ClinicalTrials.gg
RecruitingNCT06545474Early-TMSUpdated Nov 10, 2026

Effects of rTMS Compared to SSRI as Early Treatment of Depression (Early-TMS)

An interventional study of bilateral theta burst stimulation and SSRI treatment in Major Depressive Disorder, sponsored by University Hospital Tuebingen. Recruiting at 1 site in Germany. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-11-10.

Sponsored by University Hospital Tuebingen · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Sep 2024; still recruiting 2 years 2 months later.
Updated Nov 10, 2026Now RecruitingFirst site in Germany+5 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
106
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 13 studies in Depressive Disorder, Major by University Hospital Tuebingen — 3 open to participants now, 3 under way, none of them phase 3. Depressive Disorder, Major · University Hospital Tuebingen.

Planned enrollment
3rd of 13
106 · median 57
Started
2024
with 3 others
No phase
10 of 13
2 open now
Registered
11th of 13
by date

Among the 13 studies in Depressive Disorder, Major by University Hospital Tuebingen, this one is the 3rd largest by planned enrollment, is one of 4 that started in 2024, is one of 10 with no phase, and was the 11th registered.

Depressive Disorder, Major

3,051 studies on the registry are indexed under Depressive Disorder, Major; 596 are open to participants now.

Browse Depressive Disorder, Major studies →

Open to participants now

3 of the 13 studies in Depressive Disorder, Major by University Hospital Tuebingen are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

Where they have run

Who these studies take

Of the 419 Depressive Disorder, Major studies recruiting now, 93 (22%) set no upper age limit and 299 (71%) stop at 75 or younger; 55 take children under 18; 100 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 13 studies in Depressive Disorder, Major by University Hospital Tuebingen, or all of them as a file.
02

Study summary

The aim of this randomized multicentre phase 2 clinical trial is to compare the effects of rTMS and SSRI medication as early treatment of depression. In this two-stage, therapy response-adapted trial, 106 patients suffering from non-treatment resistant major depression (non-TR MD) will be randomized in Stage I to either 4 weeks bilateral theta burst stimulation (TBS) or 4 weeks antidepressant SSRI medication. The allocation to Stage II occurs therapy response-adapted. Patients receive either a maintenance treatment or a switch to the respective other treatment arm. The primary outcome is the comparison of the two study arms with regard to therapy response measured with the Montgomery-Asberg Depression Rating Scale (MADRS) after 4 weeks at the end of Stage I.

Read the detailed description

This is a therapy response-adapted, two-phase, randomized and controlled study. Initially, the study participants will be randomized to two treatment arms (Stage I: 4 weeks TBS vs. SSRI). After completion of Stage I, the allocation to Stage II (4 weeks) occurs therapy response-adapted. The type of further treatment depends on whether a remission, a treatment response or non-response has occurred in Stage I. If remission has been achieved, the treatment form already applied is continued as maintenance therapy. In the case of non-response, a switch to the other treatment arm takes place. For patients who show a treatment response but have not achieved remission, the corresponding patient preference is given special consideration for Stage II and thus determines the type of further treatment. Depending on patient preference, it is therefore possible both to continue treatment from Stage I and to switch to the other treatment arm.

The study aims to answer the question of whether a 4-week bilateral TBS is not inferior to standard antidepressant treatment with an SSRI in drug-naïve patients with MD in terms of efficacy and tolerability.

03

Conditions studied

  • Major Depressive Disorder

Keywords

  • Depression
  • non-invasive brain stimulation
  • repetitive transcranial magnetic stimulation
  • theta burst stimulation
  • non-treatment resistant depression
04

Who can participate

The criteria were revised on the registry on Nov 10, 2026. See what changed

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • male, female, or diverse gender;
  • age between 18 and 65 years;
  • moderate to severe MD according to the diagnostic criteria of ;
  • MADRS Score ≥ 20 points;
  • the duration of the episode must be at least 2 weeks and not exceed a period of 2 years;
  • no previous antidepressant treatment; indication for antidepressant medication;
  • patients must be capable of giving .

Exclusion criteria

Exclusion Criteria:

  • acute suicidal ideation (MADRS item 10 score > 4);
  • presence of psychotic symptoms;
  • antiepileptic drugs or benzodiazepines in a dosage equivalent to > 1 mg Lorazepam/d;
  • comorbid Axis I disorder (except anxiety disorders and ADHD);
  • presence of severe, , and predominant comorbid personality disorder;
  • treatment resistance defined as the failure of at least one adequate antidepressant treatment attempt in the current or previous depressive episode;
  • neurological pre-existing conditions such as severe traumatic brain injury, neoplasms, brain surgery, stroke within the last 3 months, neurodegenerative diseases: epilepsy or history of epileptic seizures;
  • cardiac pacemaker (not compatible with MRI);
  • intracranial metallic implants;
  • previous rTMS treatment;
  • deep brain stimulation;
  • other severe somatic diseases; pregnancy;
  • for the use of escitalopram.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
106 participants (estimated)

Study arms

  • Experimental
    theta burst stimulation (TBS)

    In Stage I, participants receive 4-week bilateral theta burst stimulation. Bilateral TBS consists of 20 sessions that are conducted daily from Monday to Friday over a period of 4 weeks. The target regions are the right and left dorsolateral prefrontal cortex (dlPFC). On the left hemisphere, intermittent TBS (iTBS) is applied, which has a stimulating effect on the target region similar to 10 Hz rTMS. On the right dlPFC, continuous TBS (cTBS) is applied, which has an inhibitory effect similar to 1 Hz rTMS.

    Device: bilateral theta burst stimulation

  • Active comparator
    SSRI treatment

    In Stage I, participants receive escitalopram (10mg/day) as standard medication for 4 weeks. In justified individual cases and according to the decision of the study physician, a higher dose or another SSRI can be administered.

    Drug: SSRI treatment

Interventions

  • Devicebilateral theta burst stimulation

    Each stimulation session consists of 600 stimuli applied in bursts of 3 pulses at 50 Hz, with an interstimulus interval of 200 ms. iTBS is administered 20 times for 2 seconds to the left dlPFC, with an intertrain interval of 8 seconds and cTBS continuously for 40 seconds to the right dlPFC in alternating order.

  • DrugSSRI treatment

    Participants receive 4 weeks SSRI treatment with escitalopram (10mg/day) as standard drug.

06

What researchers measure

Primary outcomes

  1. response rates after Stage I

    The primary endpoint is the comparison of the two study arms with regard to the number of participants achieving therapy response (reduction of MADRS score ≥ 50%) after 4 weeks at the end of Stage I.

    Time frame: 4 weeks

07

Study locations

1 of 1 sites recruiting
08

References and documents

Publications

  • Becker-Sadzio J, Brendel B, Weller S, Bornheimer E, Mehlig U, Padberg F, Vogelmann U, Kammer T, Strube W, Martus P, Fallgatter AJ, Plewnia C. Effectiveness of rTMS compared to SSRI as early treatment of depression - study protocol of a randomized controlled trial (Early-TMS). Eur Arch Psychiatry Clin Neurosci. 2025 Sep;275(6):1839-1849. doi: 10.1007/s00406-025-01975-4. Epub 2025 Feb 22. PubMed 39985658 ↗

Related links

Individual participant data

Plan to share: No

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2024 (actual). Primary completion is estimated for Jul 2027, 34 months after the start.

Of 654 non-industry interventional studies with no phase under Depressive Disorder, Major, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 55. This study's planned 34 months is close to that.

Counting every sponsor, half of 694 studies reached it within 33 months; a quarter within 17 and three quarters within 55.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 10, 2026: primary completion Dec 2026 → Jul 2027 and completion Dec 2026 → Dec 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Aug 5, 2024
First posted
Aug 9, 2024
StartActual
Sep 15, 2024
Primary completionEst.
Jul 31, 2027was Dec 2026
CompletionEst.
Dec 31, 2027was Dec 2026
Last update
Nov 10, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Nov 10, 2026
Sites
1 site added — first site in Germany
Show site
  • University Hospital Tuebingen · Tübingen, Germany
Nov 10, 2026
Primary completion
Dec 31, 2026→Jul 31, 2027
Nov 10, 2026
Study completion
Dec 31, 2026→Dec 31, 2027
Nov 10, 2026
Eligibility
1 exclusion criterion edited
What changed in the criteria
Exclusion criteria
  • Editedcomorbid Axis I disorder (except anxiety disorders and ADHD);
Nov 10, 2026
Publications
1 publication citing this study linked from PubMed, e.g. PubMed 39985658 ↗
Nov 10, 2026
Sponsor
Collaborators added: German Center for Mental Health; collaborators removed: German Center for Mental Health (DZPG; www.dzpg.org)
Nov 10, 2026
Show all 1 update
  1. Nov 10, 2026
    Not yet recruiting→Recruiting
    Publications 1 publication citing this study linked from PubMed, e.g. PubMed 39985658 ↗
    1 site added — first site in Germany
    Show site
    • University Hospital Tuebingen · Tübingen, Germany
    Primary completion Dec 31, 2026→Jul 31, 2027
    Study completion Dec 31, 2026→Dec 31, 2027
    Eligibility 1 exclusion criterion edited
    What changed in the criteria
    Exclusion criteria
    • Editedcomorbid Axis I disorder (except anxiety disorders and ADHD);
    Sponsor Collaborators added: German Center for Mental Health; collaborators removed: German Center for Mental Health (DZPG; www.dzpg.org)
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06545474
Collaborators
German Center for Mental Health
Responsible party
Sponsor
First posted
Aug 9, 2024
Start date
Sep 15, 2024
Primary completion
Jul 31, 2027 (estimated)
Completion
Dec 31, 2027 (estimated)
Last update
Nov 10, 2026

Study contacts

Christian Plewnia, Prof. Dr.
Contact
christian.plewnia@med.uni-tuebingen.de
+4970712984858
Julia Becker-Sadzio, Dr.
Contact
julia.becker-sadzio@med.uni-tuebingen.de
+4970712984858

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion